Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
| Market Capitalization | $268.4057 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.265 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.1 |
| EBITDA | -26,262.992 |
| Profit Margin | -2.5103 |
| Operating Margin TTM | -2.69 |
| Return on Assets TTM | -0.1865 |
| Return on Equity TTM | -0.3048 |
| Revenue TTM | 9,800.556 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2018-06-30 | ||||
| 2019-06-30 | ||||
| 2020-06-30 | 2,898.23 | |||
| 2021-06-30 | 3,288.39 | |||
| 2022-06-30 | 6,554.02 | 30,290.969 | ||
| 2023-06-30 | 11,664.82 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2018-06-30 | 8,217.108 | |||||
| 2019-06-30 | 18,963.108 | |||||
| 2020-06-30 | 5,265.49 | 9,115.01 | 956.09 | 0 | 23,933 | |
| 2021-06-30 | 8,439.07 | 22,612.87 | 2,335.31 | 0 | 44,903.522 | |
| 2022-06-30 | 55,336.328 | 99,821.943 | 7,585.409 | 0 | 132,115.43 | |
| 2023-06-30 | 5,974.82 | 76,896.41 | 7,720.74 | 0 | 132,820.32 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2018-06-30 | -1,719.112 | -1,499.364 | -1,486.975 | |||
| 2019-06-30 | -3,684.332 | -3,706.926 | 2,213.428 | |||
| 2020-06-30 | -6,953.863 | -6,830.297 | 1,374.951 | |||
| 2021-06-30 | -10,221.368 | -7,677.075 | 3,173.578 | 8,439.068 | ||
| 2022-06-30 | -23,754.583 | -13,313.918 | 46,897.26 | 8,439.068 | 55,336.328 | |
| 2023-06-30 | -24,602.446 | -27,499.96 | -24,123.24 | 55,336.328 | 31,213.092 |